Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)
Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer, most NSCLC patients are at advanced stage at the time of diagnosis. For patients without sensitive driven-oncogene mutations, chemotherapy is still the main treatment at present, the overall prognosis is poor. Im...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2020-02-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2020.02.01 |
| _version_ | 1819093195728879616 |
|---|---|
| author | Caicun ZHOU Jie WANG Hong BU Baocheng WANG Baohui HAN You LU Zhehai WANG Bo ZHU Ziping WANG Qibin SONG Shengxiang REN Dongmei LIN Yayi HE Xiaohua HU Hongyun ZHAO Shukui QIN |
| author_facet | Caicun ZHOU Jie WANG Hong BU Baocheng WANG Baohui HAN You LU Zhehai WANG Bo ZHU Ziping WANG Qibin SONG Shengxiang REN Dongmei LIN Yayi HE Xiaohua HU Hongyun ZHAO Shukui QIN |
| author_sort | Caicun ZHOU |
| collection | DOAJ |
| description | Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer, most NSCLC patients are at advanced stage at the time of diagnosis. For patients without sensitive driven-oncogene mutations, chemotherapy is still the main treatment at present, the overall prognosis is poor. Improving outcomes and obtaining long-term survival are the most urgent needs of patients with advanced NSCLC. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors (ICIs), especially targeting programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1), have made a breakthrough in the treatment of NSCLC, beneficial to patients’ survival and changed the treatment pattern for NSCLC. It shows more and more important role in the treatment of NSCLC. Led by NSCLC expert committee of Chinese society of clinical oncology (CSCO), relevant experts in this field were organized. On the basis of referring to domestic and foreign literature, systematically evaluating the results of Chinese and foreign clinical trials, and combining the experiences of the experts, the experts group reached an agreement to develop this consensus. It will guide domestic counterparts for better application of ICIs to treat NSCLC. |
| first_indexed | 2024-12-21T23:07:39Z |
| format | Article |
| id | doaj.art-fcefc911724446398f14c27c88a3df79 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-12-21T23:07:39Z |
| publishDate | 2020-02-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-fcefc911724446398f14c27c88a3df792022-12-21T18:47:07ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872020-02-01232657610.3779/j.issn.1009-3419.2020.02.01Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version)Caicun ZHOU0Jie WANG1Hong BU2Baocheng WANG3Baohui HAN4You LU5Zhehai WANG6Bo ZHU7Ziping WANG8Qibin SONG9Shengxiang REN10Dongmei LIN11Yayi HE12Xiaohua HU13Hongyun ZHAO14Shukui QIN15Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, ChinaCancer Hospital Chinese Academy of Medical Sciences, Beijing 100021, ChinaWest China Hospital, Sichuan University, Chengdu 610041, ChinaNO. 960 Hospital of PLA, Jinan 250031, ChinaShanghai Chest Hospital, Shanghai 200030, ChinaWest China Hospital, Sichuan University, Chengdu 610041, ChinaShandong Caner Hospital and Institute, Jinan 250117, ChinaChongqing Daping Hospital, Chongqing 400042, ChinaBeijing Cancer Hospital, Beijing 100142, ChinaRenmin Hospital of Wuhan University, Wuhan 430060, ChinaShanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, ChinaBeijing Cancer Hospital, Beijing 100142, ChinaShanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai 200433, ChinaThe First Affiliated Hospital of Guangxi Medical University, Nanning 530021, ChinaSun Yat-sen University Cancer Center, Guangzhou 510060, ChinaQinhuai Medical Area, Eastern Theater General Hospital of PLA China, Nanjing 210002, ChinaNon-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer, most NSCLC patients are at advanced stage at the time of diagnosis. For patients without sensitive driven-oncogene mutations, chemotherapy is still the main treatment at present, the overall prognosis is poor. Improving outcomes and obtaining long-term survival are the most urgent needs of patients with advanced NSCLC. In recent years, immunotherapy has developed rapidly. Immune checkpoint inhibitors (ICIs), especially targeting programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1), have made a breakthrough in the treatment of NSCLC, beneficial to patients’ survival and changed the treatment pattern for NSCLC. It shows more and more important role in the treatment of NSCLC. Led by NSCLC expert committee of Chinese society of clinical oncology (CSCO), relevant experts in this field were organized. On the basis of referring to domestic and foreign literature, systematically evaluating the results of Chinese and foreign clinical trials, and combining the experiences of the experts, the experts group reached an agreement to develop this consensus. It will guide domestic counterparts for better application of ICIs to treat NSCLC.http://dx.doi.org/10.3779/j.issn.1009-3419.2020.02.01lung neoplasmscancer immunotherapyimmune checkpoint inhibitorpd-1/pd-l1 |
| spellingShingle | Caicun ZHOU Jie WANG Hong BU Baocheng WANG Baohui HAN You LU Zhehai WANG Bo ZHU Ziping WANG Qibin SONG Shengxiang REN Dongmei LIN Yayi HE Xiaohua HU Hongyun ZHAO Shukui QIN Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version) Chinese Journal of Lung Cancer lung neoplasms cancer immunotherapy immune checkpoint inhibitor pd-1/pd-l1 |
| title | Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version) |
| title_full | Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version) |
| title_fullStr | Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version) |
| title_full_unstemmed | Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version) |
| title_short | Chinese Experts Consensus on Immune Checkpoint Inhibitors for Non-small Cell Lung Cancer (2019 version) |
| title_sort | chinese experts consensus on immune checkpoint inhibitors for non small cell lung cancer 2019 version |
| topic | lung neoplasms cancer immunotherapy immune checkpoint inhibitor pd-1/pd-l1 |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2020.02.01 |
| work_keys_str_mv | AT caicunzhou chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT jiewang chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT hongbu chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT baochengwang chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT baohuihan chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT youlu chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT zhehaiwang chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT bozhu chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT zipingwang chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT qibinsong chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT shengxiangren chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT dongmeilin chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT yayihe chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT xiaohuahu chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT hongyunzhao chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version AT shukuiqin chineseexpertsconsensusonimmunecheckpointinhibitorsfornonsmallcelllungcancer2019version |